(Q43955494)

28 November 2017

A comparison of pravastatin and gemfibrozil in the treatment of dyslipoproteinemia in patients with non-insulin-dependent diabetes mellitus (English)

1 reference

28 November 2017

0 references

Morris Schweitzer

1

1 reference

28 November 2017

Daniel Tessier

2

1 reference

28 November 2017

William D Vlahos

3

1 reference

28 November 2017

Lawrence Leiter

4

1 reference

28 November 2017

Jean Paul Collet

5

1 reference

28 November 2017

Matthew J McQueen

6

1 reference

28 November 2017

Laurent Harvey

7

1 reference

28 November 2017

Petar Alaupovic

8

1 reference

28 November 2017

1 May 2002

1 reference

28 November 2017

1 reference

28 November 2017

162

1 reference

28 November 2017

1

1 reference

28 November 2017

201-210

1 reference

Plasma lipid and lipoprotein levels with continuous subcutaneous insulin infusion in type I diabetes mellitus

28 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900700-6

Apolipoprotein composition as the basis for classifying plasma lipoproteins. Characterization of ApoA- and ApoB-containing lipoprotein families

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900700-6

Subpopulations of apolipoprotein A-I in human high-density lipoproteins. Their metabolic properties and response to drug therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900700-6

Effect of pravastatin, an HMG CoA reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by their apolipoprotein composition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900700-6

A multicenter comparison of the effects of simvastatin and fenofibrate therapy in severe primary hypercholesterolemia, with particular emphasis on lipoproteins defined by their apolipoprotein composition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900700-6

Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900700-6

The effect of aggressive and moderate lowering of LDL-cholesterol and low dose anticoagulation on plasma lipids, apolipoproteins and lipoprotein families in post coronary artery bypass graft trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900700-6

Drug treatment of lipid disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900700-6

Effects of gemfibrozil on low-density lipoprotein particle size, density distribution, and composition in patients with type II diabetes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900700-6

Mechanism of action of fibrates on lipid and lipoprotein metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900700-6

3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and hepatic apolipoprotein B secretion.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900700-6

Effect of gemfibrozil on high density lipoprotein subspecies in non-insulin dependent diabetes mellitus. Relations to lipolytic enzymes and to the cholesteryl ester transfer protein activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900700-6

Cholesterol efflux from human monocyte-derived macrophages in the presence of LpA-I:A-II

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900700-6

Cholesterol efflux from Fu5AH hepatoma cells induced by plasma of subjects with or without coronary artery disease and non-insulin-dependent diabetes: importance of LpA-I:A-II particles and phospholipid transfer protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900700-6

HDLs containing apolipoproteins A-I and A-II (LpA-I:A-II) as markers of coronary artery disease in men with non-insulin-dependent diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900700-6

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900700-6

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900700-6

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900700-6

10.1016/S0021-9150(01)00700-6

7 January 2021

Identifiers

DOI

1 reference

28 November 2017

1 reference